Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;32(7):823-827.
doi: 10.1111/iju.70063. Epub 2025 Apr 7.

Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study

Leandro Blas  1 , Masaki Shiota  1 , Takuma Kato  2 , Ryuji Matsumoto  3 , Yoichiro Tohi  2 , Shinichi Sakamoto  4 , Akira Yokomizo  5 , Takahiro Kimura  6 , Junya Furukawa  7 , Sunao Shoji  8 , Haruki Kume  9 , Takayuki Goto  10 , Yoshitaka Sekine  11 , Yasuyuki Sakai  12 , Yoh Matsuoka  13 , Nobuyuki Hinata  14 , Toshiyuki Kamoto  15 , Naoki Terada  16 , Shusuke Akamatsu  17 , Mikio Sugimoto  2 , Masatoshi Eto  1
Affiliations

Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study

Leandro Blas et al. Int J Urol. 2025 Jul.

Abstract

Objectives: To report outcomes of active surveillance (AS) for prostate cancer in men with intermediate-risk features of International Society of Urological Pathology (ISUP) grade group 2 and/or clinical stage T2 compared with ISUP grade group 1 and clinical stage T1 in the PRIAS-JAPAN study.

Methods: Patients with prostate cancer diagnosed between January 2010 and February 2024 were included in this study. PSA test, rectal examination, and re-biopsy were performed regularly. We calculated the pathological reclassification rate, program persistence rate, and subsequent treatment.

Results: Data from 1302 participants were collected. After excluding patients who did not fit inclusion criteria (n = 28) or follow-up of less than 1 year (n = 208), 1066 patients were included in this analysis. The median follow-up was 42.4 months (interquartile range 17.0-72.1). There were no statistical differences in the pathological reclassification, persistence rates, and subsequent therapy between low- and intermediate-risk features.

Conclusion: This preliminary study demonstrated medium-term outcomes of AS in prostate cancer with intermediate-risk features in Japan, suggesting no significant difference in the pathological reclassification, persistence rate, and subsequent therapy between low- and intermediate-risk features.

Keywords: PRIAS; active surveillance; prostate cancer; prostate‐specific antigen.

PubMed Disclaimer

References

    1. T. Kimura and S. Egawa, “Epidemiology of Prostate Cancer in Asian Countries,” International Journal of Urology 25, no. 6 (2018): 524–531, https://doi.org/10.1111/iju.13593.
    1. F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263, https://doi.org/10.3322/caac.21834.
    1. Center for Cancer Control and Information Services, National Cancer Center, “Cancer Information Service,” https://ganjoho.jp/en/public/statistics/short_pred.html.
    1. J. A. Lane, J. L. Donovan, M. Davis, et al., “Active Monitoring, Radical Prostatectomy, or Radiotherapy for Localised Prostate Cancer: Study Design and Diagnostic and Baseline Results of the ProtecT Randomised Phase 3 Trial,” Lancet Oncology 15, no. 10 (2014): 1109–1118, https://doi.org/10.1016/S1470‐2045(14)70361‐4.
    1. T. J. Wilt, M. K. Brawer, K. M. Jones, et al., “Radical Prostatectomy Versus Observation for Localized Prostate Cancer,” New England Journal of Medicine 367, no. 3 (2012): 203–213, https://doi.org/10.1056/NEJMoa1113162.

Substances